According to a recent Federal Trade Commission report, pharmacy benefit managers (PBMs), originally formed to reduce healthcare costs, have instead been found to inflate medication prices and overcharge for treatments like cancer therapies.

The FTC’s findings, following a two-year investigation, reveal that PBMs’ practices lead to higher costs for health plans, employers, and patients, especially those on Medicare. Amidst significant advocacy and legislative efforts for reform, the report underscores the need for increased transparency and regulation to prevent PBMs from profiting at the expense of patients and manufacturers. 7/11/2024